BIOMAT Database Logo BIOMAT Database Logo

Expression of the ETS2 and transferrin receptor genes in Philadelphia-positive chronic myeloid leukemia patients with a reciprocal t(3;21). 1992

M Lafage-Pochitaloff, and M Courcoul, and J Simonetti, and D Sainty, and N Dastugue, and A Tabilio, and A Hagemeijer, and F Birg
Unité 119, Institut National de la Santé et de la Recherche Médicale, Marseille, France.

The translocation t(3;21)(q26;q22) is a rare recurring clonal abnormality, either preceding or associated with blast crisis in Philadelphia chromosome-positive chronic myeloid leukemia (CML) patients. We previously localized the chromosomal breakpoints at 3q26.2 and 21q22.2, using high resolution chromosomal analysis. Two genes of interest are localized near the breakpoints, the transferrin receptor gene and the ETS2 proto-oncogene. Their chromosomal localizations, determined by in situ hybridization on normal metaphase cells, were 3q29 and 21q22.3, respectively. They underwent a reciprocal translocation in patients with t(3;21). Their structures were not altered by the translocation, and both were expressed to varying levels in t(3;21) patients. Southern blotting investigations showed that the structure of other single-copy genes, including FIM3, localized near the breakpoints, were not affected by the translocation. An analysis of ETS2 expression performed on CML patients without t(3;21) showed the presence of the transcript in 100% of the blast crises, but only in 20% of the chronic-phase patients. Thus ETS2 expression may either be linked to or play a role in CML progression.

UI MeSH Term Description Entries
D008297 Male Males
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011990 Receptors, Transferrin Membrane glycoproteins found in high concentrations on iron-utilizing cells. They specifically bind iron-bearing transferrin, are endocytosed with its ligand and then returned to the cell surface where transferrin without its iron is released. Transferrin Receptors,Transferrin Receptor,Receptor, Transferrin
D012097 Repressor Proteins Proteins which maintain the transcriptional quiescence of specific GENES or OPERONS. Classical repressor proteins are DNA-binding proteins that are normally bound to the OPERATOR REGION of an operon, or the ENHANCER SEQUENCES of a gene until a signal occurs that causes their release. Repressor Molecules,Transcriptional Silencing Factors,Proteins, Repressor,Silencing Factors, Transcriptional
D001752 Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%. Blast Phase,Blast Crises,Blast Phases,Crises, Blast,Crisis, Blast,Phase, Blast,Phases, Blast
D002874 Chromosome Mapping Any method used for determining the location of and relative distances between genes on a chromosome. Gene Mapping,Linkage Mapping,Genome Mapping,Chromosome Mappings,Gene Mappings,Genome Mappings,Linkage Mappings,Mapping, Chromosome,Mapping, Gene,Mapping, Genome,Mapping, Linkage,Mappings, Chromosome,Mappings, Gene,Mappings, Genome,Mappings, Linkage
D002891 Chromosomes, Human, Pair 21 A specific pair of GROUP G CHROMOSOMES of the human chromosome classification. Chromosome 21
D002893 Chromosomes, Human, Pair 3 A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification. Chromosome 3
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins

Related Publications

M Lafage-Pochitaloff, and M Courcoul, and J Simonetti, and D Sainty, and N Dastugue, and A Tabilio, and A Hagemeijer, and F Birg
Philadelphia-positive chronic myeloid leukemia with translocation t(3;21)
October 1988, Cancer genetics and cytogenetics,
M Lafage-Pochitaloff, and M Courcoul, and J Simonetti, and D Sainty, and N Dastugue, and A Tabilio, and A Hagemeijer, and F Birg
Translocation 3;21 in Philadelphia chromosome positive chronic myeloid leukemia at diagnosis.
June 1989, Cancer genetics and cytogenetics,
M Lafage-Pochitaloff, and M Courcoul, and J Simonetti, and D Sainty, and N Dastugue, and A Tabilio, and A Hagemeijer, and F Birg
Blastic phase of Ph1-positive chronic myeloid leukemia and t(3;21)
July 1988, Blood,
M Lafage-Pochitaloff, and M Courcoul, and J Simonetti, and D Sainty, and N Dastugue, and A Tabilio, and A Hagemeijer, and F Birg
Remission of Philadelphia positive chronic myelogenous leukemia associated with t(3;21) after bone marrow transplantation.
July 1993, Cancer genetics and cytogenetics,
M Lafage-Pochitaloff, and M Courcoul, and J Simonetti, and D Sainty, and N Dastugue, and A Tabilio, and A Hagemeijer, and F Birg
A further case of Philadelphia chromosome-positive chronic myeloid leukemia with t(3;9;22)
October 1988, Cancer genetics and cytogenetics,
M Lafage-Pochitaloff, and M Courcoul, and J Simonetti, and D Sainty, and N Dastugue, and A Tabilio, and A Hagemeijer, and F Birg
Translocation (3;21) in Philadelphia positive chronic myeloid leukemia: high resolution chromosomal analysis and immunological study on five new cases.
August 1989, Leukemia,
M Lafage-Pochitaloff, and M Courcoul, and J Simonetti, and D Sainty, and N Dastugue, and A Tabilio, and A Hagemeijer, and F Birg
Variant (3;21) translocation and megakaryocytic involvement in blastic crisis of Philadelphia positive chronic myeloid leukaemia.
April 1989, British journal of haematology,
M Lafage-Pochitaloff, and M Courcoul, and J Simonetti, and D Sainty, and N Dastugue, and A Tabilio, and A Hagemeijer, and F Birg
Emergence of Philadelphia positive chronic myeloid leukemia in a patient with Philadelphia negative acute lymphoblastic leukemia.
June 2001, Leukemia & lymphoma,
M Lafage-Pochitaloff, and M Courcoul, and J Simonetti, and D Sainty, and N Dastugue, and A Tabilio, and A Hagemeijer, and F Birg
Philadelphia-positive chronic myeloid leukemia with del(7)(p11p15)
October 1996, Cancer genetics and cytogenetics,
M Lafage-Pochitaloff, and M Courcoul, and J Simonetti, and D Sainty, and N Dastugue, and A Tabilio, and A Hagemeijer, and F Birg
Philadelphia-positive T-cell acute lymphoblastic leukemia with polymyositis, migratory polyarthritis and hypercalcemia following a chronic myeloid leukemia.
March 2002, Annals of hematology,
Copied contents to your clipboard!